… and pharmacokinetic profile of LAAM when given orally and intravenously to humans. Opioid-…
Behavioral, physiological, subjective and pharmacokinetic measures were collected before …

… Although I*-acetylmethadol derived from &methadone was less active than its enantiomorph
… Early investigations [6, 71 on the pharmacological activity of LAAM in man demonstrated …

… In addition, methadone (and possibly LAAM) is susceptible to pharmacokinetic drug …
To predict pharmacokinetics and effects of drug interactions, in vitro metabolic profiles are …

The aim of this study was to determine if substitution of daily methadone with second daily
levo-alpha-acetylmethadol (LAAM) would convert non-holders on methadone into holders on …

… on the pharmacokinetics, metabolism, drug interactions, and toxicity of LAAM in humans and
… The dynamic range is 5–300 ng/mL when using 1.0 mL of human plasma. This method has …

… must have an understanding of the pharmacokinetics and pharmacodynamics of methadone
in … General dosing guidelines, dosage conversions from other opioids and pharmacokinetic …

… This investigation demonstrates that CYP3A4 is a major CYP isoform responsible for human
LAAM N- demethylation and bioactivation in humans, but also reveals the existence of a …

… a bi-exponential curve, with a rapid α-phase, that corresponds to the … disappearance from
the plasma (α-phase, distribution) shows … So, for example, the blood concentrations of acid α 1 -…

… In conclusion, this report is the first to detail the effects of the narcotic analgesic l-α-acetylmethadol
on human cardiac K + channels. We find that l-α-acetylmethadol is a selective …

… The disposition of 1-α-acetylmethadol (LAAM) in plasma and urine was monitored by GC/CIMS
following oral administration of 10 doses (0.73–1.5 mg/kg) over 42 days, to twelve human …